CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

• Published in: Blood Vol. 133; no. 6; pp. 588 - 599
• Main Authors: Edwards, David K., Watanabe-Smith, Kevin, Rofelty, Angela, Damnernsawad, Alisa, Laderas, Ted, Lamble, Adam, Lind, Evan F., Kaempf, Andy, Mori, Motomi, Rosenberg, Mara, d'Almeida, Amanda, Long, Nicola, Agarwal, Anupriya, Sweeney, David Tyler, Loriaux, Marc, McWeeney, Shannon K., Tyner, Jeffrey W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07.02.2019; American Society of Hematology
• Subjects: Anisoles - pharmacology; Antineoplastic Agents - pharmacology; Cell Differentiation; Cell Survival; Culture Media, Conditioned - pharmacology; Female; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Male; Myeloid Neoplasia; Paracrine Communication - drug effects; Prognosis; Pyrimidines - pharmacology; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors; Survival Rate; Tumor Cells, Cultured; Tumor Microenvironment - drug effects
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2018-03-838946

To identify new therapeutic targets in acute myeloid leukemia (AML), we performed small-molecule and small-interfering RNA (siRNA) screens of primary AML patient samples. In 23% of samples, we found sensitivity to inhibition of colony-stimulating factor 1 (CSF1) receptor (CSF1R), a receptor tyrosine kinase responsible for survival, proliferation, and differentiation of myeloid-lineage cells. Sensitivity to CSF1R inhibitor GW-2580 was found preferentially in de novo and favorable-risk patients, and resistance to GW-2580 was associated with reduced overall survival. Using flow cytometry, we discovered that CSF1R is not expressed on the majority of leukemic blasts but instead on a subpopulation of supportive cells. Comparison of CSF1R-expressing cells in AML vs healthy donors by mass cytometry revealed expression of unique cell-surface markers. The quantity of CSF1R-expressing cells correlated with GW-2580 sensitivity. Exposure of primary AML patient samples to a panel of recombinant cytokines revealed that CSF1R inhibitor sensitivity correlated with a growth response to CSF1R ligand, CSF1, and other cytokines, including hepatocyte growth factor (HGF). The addition of CSF1 increased the secretion of HGF and other cytokines in conditioned media from AML patient samples, whereas adding GW-2580 reduced their secretion. In untreated cells, HGF levels correlated significantly with GW-2580 sensitivity. Finally, recombinant HGF and HS-5–conditioned media rescued cell viability after GW-2580 treatment in AML patient samples. Our results suggest that CSF1R-expressing cells support the bulk leukemia population through the secretion of HGF and other cytokines. This study identifies CSF1R as a novel therapeutic target of AML and provides a mechanism of paracrine cytokine/growth factor signaling in this disease. •CSF1R inhibition reduces cell viability in >20% of AML patient samples and is expressed on a subpopulation of supportive cells.•CSF1R activation stimulates paracrine cytokine secretion (eg, HGF), suggesting that CSF1R is a novel target of AML support cells. [Display omitted]